吉非替尼作为一线治疗非小细胞肺癌疗效及相关影响因素

目的评价吉非替尼作为一线治疗非小细胞肺癌(NSCLC)的疗效,对治疗有效率的影响相关因素进行分析。方法 92例NSCLC患者均口服吉非替尼,治疗6周后评估治疗有效率,对比性别、年龄、病理分型、分期、PS评分、吸烟情况、病灶大小、局部治疗等对治疗有效率的影响情况。结果吉非替尼一线治疗晚期NSCLC患者治疗有效率为54.3%,疾病控制率72.8%。多因素logistic回归分析显示,伴有吸烟、病灶≥3 cm以及伴有局部治疗的患者治疗有效率显著降低,差异有统计学意义(P<0.05)。结论吸烟、病灶≥3 cm、存在局部治疗患者的吉非替尼治疗有效率较低。吸烟情况,病灶大小,局部治疗是吉非替尼治疗有效率的独立危险因素。

Curative effect of gefitinib on non- small -cell lung cancer and associated factors analysis

Objective To evaluate the efficacy of gefitinib on the non-small-cell lung cancer(NSCLC)and analyze curative effect associated factors.Methods Ninety-two patients with NSCLC in our hospital,who received gefitinib,were included in this study.Curative effect was evaluated at posttreatment six weeks.The data of sex,age,pathology classification,stages,PS score,smoking,lesions size,local treatment were analyzed.Results The effective rate of gefitinib was 54.3% in NSCLC and disease control rate was 72.8%.The factors of smoking,lesions size ≥3 cm,and frequency local treatment were associated with low efficiency by logistic regression analysis(P<0.05).Conclusion Smoking,lesions size≥3 cm and local treatment were the independent risk factors of low gefitinib effective rate.